In a significant legal development, the European Union’s highest court has ruled in favor of Illumina, declaring that the European Commission lacked the authority to review its acquisition of Grail, a liquid biopsy company. According to a statement, the court’s decision nullifies the Commission’s prior actions and spares Illumina from a potentially record-breaking fine. However, the ruling arrives too late to impact the deal, as Illumina has already spun off Grail as a standalone entity amid ongoing antitrust challenges.
The case, which has spanned more than four years, was marked by Illumina’s persistent claims that the European regulators’ opposition to the acquisition was legally unfounded. Now, the Court of Justice of the European Union has validated those claims. Nevertheless, the ruling does little to change the current landscape, with Grail’s spin-out effectively making the point moot in terms of the merger’s actualization.
In response to the ruling, EU Competition Commissioner Margrethe Vestager acknowledged the court’s decision while emphasizing the broader implications for future merger reviews within the European Union. “We will carefully study the judgment and its implications,” Vestager stated, per a statement.
Related: EU Court Sides with Illumina in High-Profile Merger Case
Vestager defended the Commission’s original actions, highlighting the importance of protecting smaller, innovative companies from being eliminated by larger corporations through what she described as “killer acquisitions.” Such transactions, she noted, can be harmful to competition even when they do not meet the traditional EU notification thresholds. Per her statement
, Vestager pointed out that small firms, despite their limited turnover, can play a critical competitive role in the market, particularly when they are seen as potential innovators or future competitors.
Moving forward, the Commission will continue to accept merger referrals from Member States under Article 22 of the EU Merger Regulation, provided that the legal criteria are met. Vestager reiterated that the Commission remains committed to ensuring that transactions with significant competitive implications are subject to appropriate scrutiny, in compliance with the court’s judgment.
The ruling, though it brings a measure of legal vindication for Illumina, underscores the ongoing tension between global corporations and European regulators over the control and impact of mergers, particularly those involving cutting-edge technologies and innovation-driven companies.
Source: EC Europa
Featured News
Big Tech Braces for Potential Changes Under a Second Trump Presidency
Nov 6, 2024 by
CPI
Trump’s Potential Shift in US Antitrust Policy Raises Questions for Big Tech and Mergers
Nov 6, 2024 by
CPI
EU Set to Fine Apple in First Major Enforcement of Digital Markets Act
Nov 5, 2024 by
CPI
Six Indicted in Federal Bid-Rigging Schemes Involving Government IT Contracts
Nov 5, 2024 by
CPI
Ireland Secures First €3 Billion Apple Tax Payment, Boosting Exchequer Funds
Nov 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI